Fidaxomicin + Vancomycin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile
Conditions
Clostridium Difficile
Trial Timeline
Nov 6, 2014 → May 5, 2016
NCT ID
NCT02254967About Fidaxomicin + Vancomycin
Fidaxomicin + Vancomycin is a approved stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02254967. Target conditions include Clostridium Difficile.
What happened to similar drugs?
7 of 20 similar drugs in Clostridium Difficile were approved
Approved (7) Terminated (4) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02254967 | Approved | Completed |
Competing Products
20 competing products in Clostridium Difficile